Altimmune announced positive topline results from its Phase 2 RECLAIM trial for pemvidutide in alcohol use disorder (AUD), meeting its primary endpoint with a statistically significant reduction in heavy drinking days. This successful trial outcome, including meeting key secondary endpoints recognized by the FDA as registrational, significantly de-risks the drug's development and positions Altimmune for further discussions with the FDA, potentially leading to a pivotal Phase 3 trial.
Altimmune (ALT) announced highly positive topline results from its Phase 2 RECLAIM trial for pemvidutide in alcohol use disorder (AUD). The drug met its primary endpoint of reducing heavy drinking days and also achieved significant results on several secondary endpoints, including those recognized by the FDA as registrational. This is a major de-risking event for Altimmune, as successful Phase 2 data is crucial for advancing drug candidates. The positive results, coupled with a favorable tolerability profile, suggest a strong potential for pemvidutide in a market with high unmet need, which could lead to significant long-term revenue opportunities for Altimmune. The company's plan to request an End-of-Phase 2 meeting with the FDA indicates a clear path forward towards a potential Phase 3 trial, making this a significant short-term catalyst for the stock.